Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 32Colonic Neoplasms 8Rectal Neoplasms 7Neoplasm Metastasis 5Stomach Neoplasms 3Pancreatic Neoplasms 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Neutropenia 2Bile Duct Neoplasms 2Adenocarcinoma 2mCRC 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasms 1Nasopharyngeal Carcinoma 1Microsatellite-stable Colorectal Cancer 1Lung Neoplasms 1High-grade Extra Pulmonary Neuroendocrine Cancer 1Gastric Cancer Adenocarcinoma Metastatic 1First-line Treatment 1Esophageal Squamous Cell Carcinoma 1EFS 1Dihydropyrimidine Dehydrogenase Deficiency 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Teclison Ltd.

Phase 2 Recruiting
110 enrolled
GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡